From GlobeNewswire: 2024-11-21 07:30:00

The Blood Cancer Diagnostics Market was valued at USD 12.4 billion in 2023, with a projected 6.8% CAGR from 2024 to 2032. Rising incidence of blood cancers globally is driving market growth, with tests like blood tests playing a key role in early detection. Hospitals are expected to reach USD 9 billion by 2032, reinforcing their vital role in blood cancer diagnostics.

In the United States, the Blood Cancer Diagnostics Market is set to grow to USD 9.4 billion by 2032, driven by a focus on early detection and prevention. Investments in infrastructure and technology support this growth, with a proactive approach improving patient outcomes. Major players in the market include Abbott Laboratories, Becton, Dickinson and Company, and Thermo Fisher Scientific Inc.

Industry insights highlight key growth drivers like advancements in cancer diagnostic technologies and early screening programs. Challenges include the high cost of advanced diagnostics and stringent regulatory scenarios. The future trends in the blood cancer diagnostics market point towards a growing awareness and increasing demand for early screening programs to improve patient outcomes.



Read more at GlobeNewswire: Blood Cancer Diagnostics Market to hit USD 22.2 billion by